Paramax Diagnostics, Inc.

220, Duncan Mill Rd., M3B3J5 Toronto

Telephone +1 647 4764845
Fax +1 647 497 5844

This company is co-exhibitor of
Canadian German Chamber of Industry and Commerce Inc.

Trade fair hall

  • Hall 3 / H14
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 3): stand H14

Fairground map

MEDICA 2016 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.07  Immuno assay systems

Immuno assay systems

Our products

Product category: Immuno assay systems

PMAX Combilyzer

PMAX Combilyzer is a fully automated Chemiluminescence closed system analyzer.

More Less

Company news




Oct 5, 2016

PARAMAX feiert Messeeinstand auf der MEDICA und präsentiert innovatives Analysegerät für kleine bis mittelgroße Diagnostiklabore

Der PMAX-Combilyzer ist ein kompaktes, vollautomatisches Chemilumineszenz-Analysegerät, das mehrere Tests gleichzeitig ablaufen lassen kann.

TORONTO, 26. September 2016— PARAMAX Diagnostics Inc. feiert sein Debüt auf der MEDICA, der weltweit größten, jährlich stattfindenden Medizinfachmesse in Düsseldorf. Vom 14.-17. November präsentiert das Unternehmen seinen auf mehreren patentierten Verfahren basierenden PMAX-Combilyzer, ein integriertes in-vitro-Analyse-Gerät, das vor allem für kleine Testlabore im Vergleich mit ihren größeren Wettbewerbern einen Vorteil darstellt.

„Die meisten diagnostischen Testergebnisse in zentral verwalteten Gesundheitssystemen, wie wir sie in Europa und Nordamerika haben, kommen aus großen Labors. Das bedeutet, dass Patienten häufig mehrere Tage oder länger auf ihre Ergebnisse warten müssen, bis es sich für das große Labor lohnt, angesichts einer entsprechend hohen Zahl ähnlicher Proben die Testverfahren durchzuführen“, erklärt Steve Mogen, Business Development Manager bei Paramax. „Doch mit dem PMAX-Combilyzer müssen keine Maschinen angepasst oder Verfahren geändert werden. Sie können einfach mehrere unterschiedliche Tests gleichzeitig laufen lassen.“

Mogen verweist auch auf die Vorteile des Combilyzer in Notsituationen: „Nehmen Sie den Herzstillstand bei einem Patienten. Da müssen mehrere Tests gleichzeitig durchgeführt werden, damit Entscheidungen schnell getroffen werden können. In so einem Fall brauchen Sie Ergebnisse von vielleicht vier verschiedenen Tests – und zwar sofort.“

Mogen ergänzt, dass das System seines Unternehmens für ein kleines Labor, das vielleicht nur zwischen 50 und 200 Proben pro Tag abarbeitet, sehr kosteneffektiv ist. Gerade für Regionen wie den Nahen Osten und Afrika ist der PMAX -Combilyzer besonders attraktiv, weil aufgrund der fehlenden Vernetzung des Gesundheitssystems dort große Labors oft nicht wirtschaftlich sind. „In Indien zum Beispiel werden Labortests von Tausenden kleiner Labore im ganzen Land durchgeführt.

 Aber auch in Ländern wie Kanada mit zentral verwalteten Gesundheitssystem in jeder einzelnen Region des Landes hat der PMAX-Combilyzer Vorteile.

„Es gibt einige Labore, wo Sie Zugriff auf Testergebnisse über das Internet haben. Wenn ein Labor den Combilyzer verwendet, können Ärzte ihren Patienten oft noch am selben Tag die Testergebnisse mitteilen“, sagt Mogen.

Der Combilyzer besitzt die amerikanische FDA-Zulassung und hat auch das CE-Zeichen für den Vertrieb in Europa und allen Ländern, die die CE-Kennzeichnung anerkennen.

Wenn Sie mehr über PARAMAX erfahren wollen, besuchen Sie uns doch auf der MEDICA 2016 am Ontario-Kanada-Gemeinschaftspavillon, Halle 3, Stand H14.

Auf der MEDICA-Website finden Sie uns auch unter Firmen & Produkte. 


Kathy Richards

Business Developer

+1 647 476 4845

More Less

Oct 5, 2016

PARAMAX to make its MEDICA debut featuring innovative new diagnostic analyzer for small to medium-sized diagnostic testing labs

The PMAX Combilyzer is a compact, fully automated Chemiluminesence analyzer capable of running multiple tests simultaneously

TORONTO,  Sept. 26, 2016 – PARAMAX Diagnostics Inc. will make its debut at MEDICA, the world’s largest annual medical trade fair, November 14-17 in Düsseldorf, Germany where it will introduce the patent-laden PMAX Combilyzer, a closed system in-vitro analyzer aimed at giving smaller diagnostic test labs an edge over larger competitors.

“Most diagnostic test results in centralized health care systems such as we have in Europe and North America come from large labs, which means patients may have to wait several days or more for their results while the large lab gathers enough similar samples to justify changing their machines and adjusting their procedures to make running a specific test profitable,” explains Steve Mogen, Paramax’s Business Development Manager. “But with the PMAX Combilyzer you don’t have to change machines or procedures; you can run several different tests on it all at once.”

 Mogen also points out the advantage of the Combilyzer’s multi-testing abilities in an emergency situation: “For instance, for cardiac arrest patients for whom decisions have to be made quickly, you don’t want to wait on one-at-a-time testing. For them, you want to know the results of maybe four different tests, and you want to know all the results immediately.”

 Also Mogen adds, having just one machine for a smaller lab that may only be handling 50  to 200 samples a day is very cost effective. Consequently, the PMAX Combilyzer is particularly attractive to regions such as the Middle East and Africa among others where healthcare is not centralized and therefore large labs are not economic. “In India, for example, lab tests are done by thousands of small labs spread all over the country.”

 But even in centralized healthcare jurisdictions such as Canada has in each province and territory there are advantages to the PMAX Combilyzer.

 “There are some labs where you can have online access to test results via the internet, so if the lab is using the Combilyzer that means for some physicians and their patients, they could have all their test results back in hours the same day,” says Mogen.
P-Max Combilyzer is approved and cleared by the FDA. It is also certified with the CE Mark, allowing its Commercial distribution in Europe as well as in all countries recognizing the CE Mark.

To learn more about PARAMAX, please visit us during MEDICA 2016 at the Ontario/Canada Pavilion, Hall 3, Booth H14.

 You can also locate us in “Companies & Products" on the portal. 


Kathy Richards

Business Developer

+1 647 476 4845

More Less

Sep 29, 2016

Paramax Diagnostics released new Vitamin D Pmax EIA assay

In Paramax Diagnostics, Inc. we provide 25-OH Vitamin D Pmax EIA which is a Quantitative Determination of Folate Concentration in Human Serum by a Microplate Enzyme Immunoassay Colorimetric  method for use in clinical laboratories.  Vitamin D is both a hormone and vitamin. Composed of a group of fat-soluble secosteroids, Vitamin D enhances intestinal absorption of calcium, iron, magnesium, phosphate and zinc, playing a crucial role in human bone health. Its chief components are Vitamin D3 (cholecalciferol) and Vitamin D2 (ergocalciferol). While both can be ingested from supplements, few foods contain Vitamin D. Sun exposure acts as the main source of Vitamin D3 in humans but is dependent on UVB radiation and often limited by sunscreen, other barriers or time spent outdoors as measures to reduce the risk of cancer.

More Less

Sep 27, 2016

Paramax Diagnostics Released PMAX Combilyzer.

Paramax Diagnostics Released PMAX Combilyzer which is a fully automated Chemiluminescence closed system analyzer .PMAX Combilyzer is a high sensitive instrument for the chemiluminescence applications. With the host of patented features, PMAX Combilyzer automation gives your lab the speed and quality you demand. With the unique general specifications like the Intelligent Rack system and the On-Board Camera as well as the high precision Micro-Syringe and Orbital MTP shaker and also the various custom reagent positions you will get the improved operation and quality for your lab .

More Less

Sep 26, 2016

palmParamax Diagnostics released new Folate Pmax CLIA assay

In Paramax Diagnostics, Inc. we provide Folate Pmax CLIA which is a Quantitative Determination of Folate Concentration in Human Serum by a Microplate Enzyme Chemiluminescence method for use in clinical laboratories.  Folate supplementation has escalated over recent years with the knowledge of its many benefits .As one of the B vitamins, folate or vitamin B9 , is involved in many bodily functions and deficiency can cause disease in not only the elderly but infants too .Folate deficiency is associated with megaloblastic anemia ,neural tube defects and cardiovascular diseases .

More Less

About us

Company details

Paramax diagnostics Inc. is a leading supplier of high-technology Laboratory products in Canada.

At Paramax, we are committed to improving the effectiveness and efficiency of the in-vitro diagnostic solution, which specializes us in a wide range of in-vitro diagnostic products including allergy, anemia, tumor markers, cardiac markers, bone metabolism, thyroid, neonatal, fertility, growth deficiency, infectious disease, and steroids.

We work side by side with a range of clients, including diagnostic laboratories, pharmaceutical and biotechnology companies, and university research centers. Our expertise extends to developing and manufacturing instruments and components. Whatever the project–large or small, simple or complex–helping our clients to achieve their goals comes first.

Paramax is motivated to improve healthcare. Our sales team consistently strives to match products' features and benefits directly with our clients' needs.

Besides its own outstanding commitment to research and development, Paramax Diagnostics Inc. has initiated and supports several non-profit organizations, primarily active in basic research and interdisciplinary knowledge transfer in In-vitro diagnostics products.

Paramax is a ISO 9001 and ISO 13485 certified medical device manufacturer.

More Less

Company data

Area of business
  • Laboratory Equipment
  • Diagnostics